Evidence map›Paper›PMID 36397778›Full record

ArticleJournal of the Endocrine Society2022

Classic and Follicular Variant of Papillary Thyroid Microcarcinoma: 2 Different Phenotypes Beyond Tumor Size.

Clotilde Sparano, Mario Rotondi, Valentina Verdiani, Paolo Brunori, Francesca Castiglione, Caterina Bartoli, Giuliano Perigli, Benedetta Badii, Vania Vezzosi, Gabriele Simontacchi and 4 more

Abstract read
In one paragraph

Article in Journal of the Endocrine Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Clotilde SparanoEndocrinology Unit, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.ORCID https://orcid.org/0000-0002-3766-4682
Mario RotondiIstituti Clinici Scientifici Maugeri IRCCS, Unit of Internal Medicine and Endocrinology, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.ORCID https://orcid.org/0000-0001-6464-2334
Valentina VerdianiEndocrinology Unit, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.
Paolo BrunoriInternational Inequality Institute, London School of Economics, London, UK.
Francesca CastiglioneDepartment of Histopathology and Molecular Diagnostics, Careggi Hospital, Florence, Italy.
Caterina BartoliDepartment of Histopathology and Molecular Diagnostics, Careggi Hospital, Florence, Italy.
Giuliano PerigliUnit of General and Endocrine Surgery, Centre of Oncological and Minimally Invasive Surgery, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.
Benedetta BadiiUnit of General and Endocrine Surgery, Centre of Oncological and Minimally Invasive Surgery, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.
Vania VezzosiDepartment of Histopathology and Molecular Diagnostics, Careggi Hospital, Florence, Italy.
Gabriele SimontacchiRadiation Oncology Unit, Careggi Hospital, Florence, Italy.
Lorenzo LiviRadiation Oncology Unit, Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
Lorenzo AntonuzzoClinical Oncology Unit, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Mario MaggiEndocrinology Unit, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.
Luisa PetroneEndocrinology Unit, Medical-Geriatric Department, Careggi Hospital, Florence, Italy.ORCID https://orcid.org/0000-0002-2167-8844

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Context: Despite the wide revision of current guidelines, the management of papillary thyroid microcarcinoma (mPTC) still has to be decided case by case. There is conflicting evidence about the role of more frequent histological subtypes, and no data about potential differences at presentation. Objective: Our aim was to compare the phenotype of the 2 most frequent mPTC variants, namely, classical papillary thyroid microcarcinoma (mPTCc) and the follicular variant of papillary thyroid microcarcinoma (mFVPTC) . Methods: Retrospective observational study, from January 2008 to December 2017 of a consecutive series of patients with mPTCc and mFVPTC. All cases were classified according to the 2015 American Thyroid Association (ATA) risk classification. Clinical and preclinical features of mPTCc and mFVPTC at diagnosis were collected. The comparison was also performed according to the incidental/nonincidental diagnosis and differences were verified by binary logistic analysis. Results: In total, 235 patients were eligible for the analysis (125 and 110 mPTCc and mFVPTC, respectively). Compared with mPTCc, mFVPTCs were more often incidental and significantly smaller (4 vs 7 mm) ( Conclusion: mFVPTC shows some differences in diagnostic presentation compared with mPTCc, and seems to retain a significant number of favorable features, including a prevalent onset as incidental diagnosis.

Indexed as

papillary thyroid microcarcinomaphenotyperisk assessmentthyroid neoplasms

Identifiers

PMID36397778
PMCPMC9664971

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.